Purine nucleoside phosphorylase. 1. Structure-function studies. 1997

M D Erion, and K Takabayashi, and H B Smith, and J Kessi, and S Wagner, and S Hönger, and S L Shames, and S E Ealick
Central Research Laboratory, Ciba-Geigy Ltd., Basel, Switzerland. mark.erion@gensia.com

To probe the catalytic mechanism of human purine nucleoside phosphorylase (PNP), 13 active-site mutants were constructed and characterized by steady-state kinetics. In addition, microtiter plate assays were developed for both the phosphorolytic and synthetic reactions and used to determine the kinetic parameters of each mutant. Mutations in the purine binding site exhibited the largest effects on enzymatic activity with the Asn243Ala mutant resulting in a 1000-fold decrease in the kcat for inosine phosphorolysis. This result in combination with the crystallographic location of the Asn243 side chain suggested a potential transition state (TS) structure involving hydrogen bond donation by the carboxamido group of Asn243 to N7 of the purine base. Analogous to the oxyanion hole of serine proteases, this hydrogen bond was predicted to aid catalysis by preferentially stabilizing the TS as a consequence of the increase in negative charge on N7 that occurs during glycosidic bond cleavage and the associated increase in the N7-Asn243 hydrogen bond strength. Two residues in the phosphate binding site, namely His86 and Glu89, were also predicted to be catalytically important based on their alignment with phosphate in the X-ray structure and the 10-25-fold reduction in catalytic activity for the His86Ala and Glu89Ala mutants. In contrast, catalytic efficiencies for the Tyr88Phe and Lys244Ala mutants were comparable with wild-type, indicating that the hydrogen bonds predicted in the initial X-ray structure of PNP [Ealick, S. E., et al. (1990) J. Biol. Chem. 265, 1812-1820] were not essential for catalysis. These results provided the foundation for studies reported in the ensuing two manuscripts focused on the PNP catalytic mechanism [Erion, M. D., et al. (1997) Biochemistry 36, 11735-11748] and the use of mutagenesis to reverse the PNP substrate specificity from 6-oxopurines to 6-aminopurines [Stoeckler, J. D., et al. (1997) Biochemistry 36, 11749-11756].

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009705 Nucleosides Purine or pyrimidine bases attached to a ribose or deoxyribose. (From King & Stansfield, A Dictionary of Genetics, 4th ed) Nucleoside,Nucleoside Analog,Nucleoside Analogs,Analog, Nucleoside,Analogs, Nucleoside
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D011683 Purine-Nucleoside Phosphorylase An enzyme that catalyzes the reaction between a purine nucleoside and orthophosphate to form a free purine plus ribose-5-phosphate. EC 2.4.2.1. Inosine Phosphorylase,Nicotinamide Riboside Phosphorylase,Purine Nucleoside Phosphorylases,Nucleoside Phosphorylases, Purine,Phosphorylase, Inosine,Phosphorylase, Nicotinamide Riboside,Phosphorylase, Purine-Nucleoside,Phosphorylases, Purine Nucleoside,Purine Nucleoside Phosphorylase,Riboside Phosphorylase, Nicotinamide
D011687 Purines A series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases. They include ADENINE and GUANINE, constituents of nucleic acids, as well as many alkaloids such as CAFFEINE and THEOPHYLLINE. Uric acid is the metabolic end product of purine metabolism.
D002384 Catalysis The facilitation of a chemical reaction by material (catalyst) that is not consumed by the reaction. Catalyses
D003198 Computer Simulation Computer-based representation of physical systems and phenomena such as chemical processes. Computational Modeling,Computational Modelling,Computer Models,In silico Modeling,In silico Models,In silico Simulation,Models, Computer,Computerized Models,Computer Model,Computer Simulations,Computerized Model,In silico Model,Model, Computer,Model, Computerized,Model, In silico,Modeling, Computational,Modeling, In silico,Modelling, Computational,Simulation, Computer,Simulation, In silico,Simulations, Computer
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006860 Hydrogen Bonding A low-energy attractive force between hydrogen and another element. It plays a major role in determining the properties of water, proteins, and other compounds. Hydrogen Bonds,Bond, Hydrogen,Hydrogen Bond

Related Publications

M D Erion, and K Takabayashi, and H B Smith, and J Kessi, and S Wagner, and S Hönger, and S L Shames, and S E Ealick
April 1978, The Journal of clinical investigation,
M D Erion, and K Takabayashi, and H B Smith, and J Kessi, and S Wagner, and S Hönger, and S L Shames, and S E Ealick
February 2010, Acta crystallographica. Section D, Biological crystallography,
M D Erion, and K Takabayashi, and H B Smith, and J Kessi, and S Wagner, and S Hönger, and S L Shames, and S E Ealick
January 2013, Biomeditsinskaia khimiia,
M D Erion, and K Takabayashi, and H B Smith, and J Kessi, and S Wagner, and S Hönger, and S L Shames, and S E Ealick
June 1979, Nihon rinsho. Japanese journal of clinical medicine,
M D Erion, and K Takabayashi, and H B Smith, and J Kessi, and S Wagner, and S Hönger, and S L Shames, and S E Ealick
June 1973, FEBS letters,
M D Erion, and K Takabayashi, and H B Smith, and J Kessi, and S Wagner, and S Hönger, and S L Shames, and S E Ealick
January 1980, Immunological communications,
M D Erion, and K Takabayashi, and H B Smith, and J Kessi, and S Wagner, and S Hönger, and S L Shames, and S E Ealick
November 2004, Nihon rinsho. Japanese journal of clinical medicine,
M D Erion, and K Takabayashi, and H B Smith, and J Kessi, and S Wagner, and S Hönger, and S L Shames, and S E Ealick
January 2000, Ryoikibetsu shokogun shirizu,
M D Erion, and K Takabayashi, and H B Smith, and J Kessi, and S Wagner, and S Hönger, and S L Shames, and S E Ealick
January 2003, Nihon rinsho. Japanese journal of clinical medicine,
M D Erion, and K Takabayashi, and H B Smith, and J Kessi, and S Wagner, and S Hönger, and S L Shames, and S E Ealick
January 1991, Immunodeficiency reviews,
Copied contents to your clipboard!